10:26 AM EDT, 08/25/2025 (MT Newswires) -- Argenx's (ARGX) Vyvgart, which was launched in 2022, is expected to see an accelerated uptake, RBC said in a Monday research note. Vyvgart is a therapy used to treat severe autoimmune diseases.

Based on its survey, RBC said the uptake might result from higher usage, convenient at-home dosing, lack of any upcoming disruptive competition, and geographical expansion.

RBC analysts expected rest of 2025 to be "relatively light" for Argenx, and said they were "buyers into a very busy 2026-2027 that could potentially more than triple current total addressable market."

The firm initiated its coverage on Argenx with an outperform rating and a $850 price target.

Price: 695.13, Change: +35.13, Percent Change: +5.32